Analyst Price Target is $29.60
▲ +123.40% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for 2seventy bio in the last 3 months. The average price target is $29.60, with a high forecast of $34.00 and a low forecast of $28.00. The average price target represents a 123.40% upside from the last price of $13.25.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in 2seventy bio.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.